Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : progenics -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (45)	5/15/2000 12:53:00 PM
From: Jim Oravetz	Read Replies (2) \| Respond to of 139

SEATTLE, May 15 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced new findings on the structure of PRO 542, an antibody-like molecule that is the Company's most advanced HIV therapy. The results provide new insights into the antiviral activity of this promising agent and were presented at the Joint Annual Meeting of the American Association of Immunologists and the Clinical Immunology Society. Progenics scientists and their collaborators used electron microscopy to visualize the structure of PRO 542 alone, and complexed with the HIV envelope glycoprotein gp120, which protrudes from the virus and mediates viral entry into target cells. Professor Kenneth H. Roux, Ph.D., of the Structural Biology Program at Florida State University (Tallahassee, FL) described the structure of PRO 542 in complex with four molecules of gp120. This detailed molecular picture demonstrates that PRO 542 possesses exceptional structural flexibility. As a result, PRO 542 may be uniquely able to neutralize HIV by crosslinking as many as four gp120s on the surface of one or more virus particles siliconinvestor.com